Morgan Stanley Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM - Get Free Report) had its target price boosted by investment analysts at Morgan Stanley from $102.00 to $108.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective points to a potential upside of 3.26% from the stock's current price.

A number of other research analysts have also issued reports on INSM. UBS Group cut their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 8th. The Goldman Sachs Group raised their price target on shares of Insmed from $100.00 to $112.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Jefferies Financial Group restated a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. Finally, Royal Bank Of Canada raised their price target on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and a consensus target price of $108.47.

Insmed Price Performance

INSM opened at $104.59 on Thursday. Insmed has a 1 year low of $60.40 and a 1 year high of $106.83. The business's 50-day moving average is $85.41 and its two-hundred day moving average is $78.02. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. The firm has a market capitalization of $19.84 billion, a PE ratio of -17.58 and a beta of 0.90.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. During the same period in the previous year, the company earned ($1.06) EPS. The company's revenue was up 22.9% on a year-over-year basis. Research analysts anticipate that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 9,925 shares of the business's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $65.47, for a total value of $649,789.75. Following the transaction, the insider directly owned 86,596 shares of the company's stock, valued at approximately $5,669,440.12. The trade was a 10.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at $8,352,401.94. This represents a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 548,197 shares of company stock valued at $49,124,834. 3.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC grew its stake in shares of Insmed by 47.1% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock worth $399,000 after purchasing an additional 1,673 shares during the period. Sowell Financial Services LLC purchased a new stake in shares of Insmed in the 1st quarter worth about $255,000. GAMMA Investing LLC boosted its position in shares of Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 386 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Insmed by 16.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock worth $288,000 after buying an additional 541 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Insmed by 37.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company's stock worth $1,521,000 after buying an additional 5,453 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.